Antimicrobials from an epigenetics based fungal metabolite screening program
US-2017050946-A1 · Feb 23, 2017 · US
Epigenetic modification of fungi and uses thereof
US12180524B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12180524-B2 |
| Application number | US-202117406025-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 18, 2021 |
| Priority date | Aug 16, 2018 |
| Publication date | Dec 31, 2024 |
| Grant date | Dec 31, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Described herein are methods of epigenetic modification of fungi and uses thereof. Also described herein are compounds that can have antileishmanial activity and formulations thereof. Also described herein are methods of treating leishmanial infection in a subject that include the step of administering a compound or formulation thereof described herein to the subject.
First claim
Opening claim text (preview).
At least the following is claimed: 1. A composition comprising Compound (1) 2. The composition of claim 1 , wherein the composition comprises an amount of Compound 1 effective to kill and/or inhibit a leishmanial parasite. 3. A pharmaceutical formulation comprising: an amount of Compound (1) and a pharmaceutically acceptable carrier. 4. The pharmaceutical formulation of claim 3 , wherein the amount is an effective amount sufficient to kill a leishmanial parasite, inhibit a leishmanial parasite, or both. 5. The pharmaceutical formulation of claim 3 , wherein the amount of Compound (1) is from about 0.01 μg to about 1000 mg or more.
Assignees
Inventors
Classifications
Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis · CPC title
- A61K31/366Primary
having six-membered rings, e.g. delta-lactones · CPC title
Fungi (culture of mushrooms A01G18/00; as new plants A01H15/00); Culture media therefor · CPC title
- C12P17/181Primary
Heterocyclic compounds containing oxygen atoms as the only ring heteroatoms in the condensed system, e.g. Salinomycin, Septamycin · CPC title
Fungi {; Processes using fungi} · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12180524B2 cover?
- Described herein are methods of epigenetic modification of fungi and uses thereof. Also described herein are compounds that can have antileishmanial activity and formulations thereof. Also described herein are methods of treating leishmanial infection in a subject that include the step of administering a compound or formulation thereof described herein to the subject.
- Who is the assignee on this patent?
- Univ South Florida, Inst Politecnico Nacional, Univ King Abdulaziz
- What technology area does this patent fall under?
- Primary CPC classification A61K31/366. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).